Skip to content
A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy
All contributors

Onconephrology contributor

Suarez, Eloah Rabello

Primarily Cellular therapy renal effects#42 of 46 recognized
  • #5 in Cellular therapy renal effects
5
Clinical papers
434
Citations (iCite)
1 / 3
First / senior author
2016–2026
Active years

Output over time

Clinical corpus papers per year — peak 1 in 2016, 2022, 2024, 2025, 2026.

  • 2016: 1 paper
  • 2022: 1 paper
  • 2024: 1 paper
  • 2025: 1 paper
  • 2026: 1 paper
20162026

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Cellular therapy renal effects5

Frequent co-authors

Other recognized contributors who most often share corpus papers with Suarez (shared-paper count).

Marasco, Wayne A3

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 40589005 (opens PubMed in a new tab)PMID 40774229 (opens PubMed in a new tab)PMID 38195534 (opens PubMed in a new tab)PMID 35326544 (opens PubMed in a new tab)PMID 27145284 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.